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Abstract: 
No standard criteria exist for assessing response and progression in clinical trials involving 
patients with meningioma and there is no consensus on the optimal endpoints for trials currently 
underway. As a result, there is substantial variation in the design and response criteria of 
meningioma trials, making comparison between trials difficult. In addition, future trials should 
be designed with accepted standardized endpoints. The Response Assessment in Neuro-
Oncology Meningioma Working Group is an international effort to develop standardized 
radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we 
present the recommendations for response criteria and endpoints for clinical trials involving 
patients with meningiomas. 
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Background 
Meningiomas are the most common type of primary brain tumors in adults, accounting for 
approximately 36% of the total, with an annual incidence of approximately 7.6 per 100,000.
1
 
These tumors are classified by the World Health Organization (WHO) classification into three 
histologic grades. Using modern WHO criteria approximately 70-75% of surgically-resected 
meningiomas are grade I (benign), 20-30% are grade II (atypical), and 1-3% are grade III 
(anaplastic or malignant).
2,3-6 
 
Small asymptomatic tumors that are not associated with surrounding edema or 
concerning radiologic features raising the specter of a higher-grade lesion can be safely observed 
with scheduled follow up imaging. Large, growing, or symptomatic meningiomas require 
treatment, most frequently with surgery with or without radiation therapy. Occasionally, 
meningiomas refractory to surgery and radiation (radiosurgery (SRS), stereotactic- or non-
stereotactic fractioned radiotherapy) prompt medical therapies, although the results of these 
medical treatments to date have been disappointing.
7-10
 
Currently, there are no standardized response criteria or clinical trial endpoints in studies 
involving meningiomas. Many trials use a variation of the Macdonald Criteria which was 
developed for high-grade gliomas for determination of response and progression,
7,9,11
 while 
others use the RECIST criteria developed for systemic tumors.
12
 These differences in response 
criteria make it difficult to compare one study to another. Moreover, no consistent definition 
exists for measurable disease, target lesions, or how to handle “pseudoprogression” related to 
treatments such as stereotactic radiosurgery or immunotherapy. There is a need for standardized 
response criteria in clinical trials involving meningiomas. 
Similarly, there are currently no generally accepted endpoints for clinical trials of 
meningioma. Some trials use response rates based on reduction of lesion size, but this only 
occurs in a minority of patients even with effective therapy, especially for grade I 
meningiomas.
9,13
 Many trials of recurrent meningiomas use 6-month or 12-month progression 
free survival (PFS).
9
 Recently, the Response Assessment In Neuro-Oncology (RANO) Working 
Group evaluated the historic data from clinical trials involving medical therapies for 
meningioma.
9
 The weighted 6-month progression-free survival (PFS6) for WHO grade I 
meningioma was 29% (95% confidence interval [CI]:20.3%–37.7%). For WHO grade II/III 
meningioma, the weighted average PFS-6 was 26% (95% CI: 19.3%–32.7%). 
The RANO Working Group established a Meningioma Subcommittee to evaluate the 
available data regarding response criteria and endpoints in clinical trials of meningioma. This 
committee consists of neuro-oncologists, neurosurgeons, radiation oncologists, 
neuroradiologists, and biostatisticians. Here, we propose consensus criteria for determining 
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response in clinical trials involving meningiomas and discuss the most appropriate endpoints and 
trial designs. When appropriate, there is similarity in language to RANO criteria proposed for 
low- and high-grade gliomas and brain metastases to ensure as much consistency as possible in 
response criteria across different brain tumor types.
14-16
  
 
Scope and Application 
Integral to the practical utility of response assessment criteria for both everyday practice and the 
clinical trial setting is that numerical cutoffs incorporated to define response categories reflect 
changes that are felt to be clinically meaningful following therapeutic intervention. Historically, 
a 25% increase in bi-dimensional product to define progression and a 50% decrease to define 
partial response have been incorporated in response assessment criteria for high-grade glioma 
and low-grade glioma because these numerical cutoffs are agreed upon to likely be clinically 
meaningful. Similar cutoffs are proposed herein and are felt to be appropriate for patients with 
meningiomas that demonstrate faster growth because these cutoffs are also felt to reflect a 
clinically meaningful change for such tumors.  
However, a substantial subset of meningioma tumors exhibit indolent and insidious growth. For 
these slow-growing tumors, numerical cutoffs of change in tumor size, particularly if increasing, 
are, by themselves, of limited value in the assessment of a therapeutic intervention, unless they 
also incorporate the variable of time. Therefore, the scope of the criteria detailed herein is 
intended to apply to patients with fast growing meningiomas. Although arbitrary, a fast-growing 
meningioma can be defined as one that has demonstrated a ≥ 15% increase in bi-dimensional 
enhancing product in the past six months. Meningioma patients with slow growing tumors, 
defined as <15% increase in bi-dimensional product over the preceding six months, will require 
modification of the proposed guidelines discussed below, including longer periods of evaluation. 
These criteria will need to incorporate numerical cutoffs of change in tumor size over time (i.e. 
tumor growth rate) in order to effectively assess the value of specific therapeutic interventions 
for such tumors.  
 
Specifications of Methods of Measurement 
Method of Assessment:  
Standardized imaging acquisition technique and radiographic assessment methods should be 
used to characterize each lesion at baseline and during follow-up. It is important to use imaging 
techniques that are consistent across all imaging time points to ensure that the assessment of 
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interval appearance or disappearance of lesions or of change in size are not affected by scan 
parameters. 
Imaging Modality:  
Gadolinium-enhanced MRI is the most sensitive and reproducible method currently available to 
measure CNS lesions selected for response assessment.  Although MRI is strongly encouraged as 
the default standard imaging technique, CT with and without contrast could be considered in 
select circumstances (e.g. lack of availability or contraindication for MRI). 1.5 or 3T MRI 
scanners are recommended, and ideally patients should be imaged on the same MRI or at least on 
MRIs with the same field strengths throughout the period of assessment.  Use of thin-section 
imaging is recommended, ideally with <=1.5 mm pixel resolution, especially for evaluating 
lesions < 10 mm in maximal diameter and/or small changes in lesion size. One option is to adapt 
the proposed standardized Brain Tumor Imaging Protocol developed for gliomas also for 
meningioma trials.
17
 In some cases, metabolic imaging (i.e. PET) could be proposed to 
meningioma patients although the evidence supporting the use of this imaging modality is 
limited and restricted to diagnosis (i.e. grading) or tumor delineation (i.e. planning of radiation 
therapy).
18
 There are also parallel efforts by the PET RANO workgroup to develop response 
criteria based on radiolabeled somatostatin receptor PET techniques that are currently evaluated 
in meningioma trials. 
 
Imaging Definitions  
Definition of Measurable Disease:  
Measurable disease is defined as bi-dimensionally contrast enhancing lesions with clearly 
defined margins by CT or MRI, with two perpendicular diameters of at least 10 mm, visible on 
two or more axial slices that are preferably, at most, 5 mm interslice thickness with no more than 
1 mm interslice gap. As with the RANO criteria for HGG and RECIST version 1.1, in the event 
the MRI is performed with thicker slices, the size of a measurable lesion at baseline should be 
two times the slice thickness.
12,14
  In the event there are interslice gaps, this also needs to be 
considered in determining the size of measurable lesions at baseline.
14
 Measurement of tumor 
around a cyst or surgical cavity represents a particular challenge. In general, such lesions should 
be considered non-measurable unless there is a nodular component measuring more than 10 mm 
in each of 2 dimensions. The cystic or surgical cavity should not be measured in determining 
response. 
 For previously treated lesions, we recommend documenting how each lesion was 
previously treated [i.e., surgical resection, SRS, fractionated radiation therapy, brachytherapy, 
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etc.]. Lesions with prior local treatment can be considered measurable if there has been 
demonstrated progression since the time of local treatment. However, careful consideration 
should be given particularly to lesions previously treated with SRS given the possibility of 
treatment effect (discussed further below in the special consideration section). Whether such 
lesions can be considered measurable as a target lesion should be specified prospectively in the 
clinical protocol. If lesions not previously treated with local therapies are present, these are 
preferred for selection as target lesions. 
 
Definition of Non-Measurable Disease:  
Non-measurable disease is defined as lesions with maximal perpendicular diameter measures 
less than 10 mm or measurable in one dimension only, or masses with ill-defined margins. 
Patients without measurable disease, such as those with non-measurable disease only or those 
who undergo a complete resection, cannot be evaluated using response based on lesion size 
reduction and can only achieve stable disease as their best radiographic outcome. A potential 
caveat are small, less than measurable, but well circumscribed lesions that disappear completely 
with treatment, in which case complete response (CR) would probably be the correct tumor 
biological assessment. Yet, for consistency within the RANO framework, only disappearance of 
measurable lesions should be labeled CR. Accordingly, if response rate is the primary endpoint 
of the study, patients with measurable disease are generally required for study eligibility. If 
duration of tumor control or survival is the primary endpoint, then patients with both measurable 
and non-measurable disease would be eligible for assessment because the determination of 
disease progression would be the primary interest. 
Evaluation of Small Lesions: 
We recognize that many patients with meningiomas present with small sub-centimeter lesions 
and that some centers routinely perform MRI imaging with 3 mm slice thickness or less. There 
was debate within the group whether the lower size limit of a measurable lesion could be reduced 
to two perpendicular diameters of at least 5 mm or even less. However, the consensus was to 
maintain consistency with RECIST 1.1 and the RANO criteria for gliomas and brain metastases 
given concerns about reproducibility and interpretation in changes of small lesions.
12,14
 Patients 
with non-measurable disease can still be included on trials where response is not the primary 
endpoint (for example, on trials with progression-free survival (PFS), overall survival (OS), or 
other primary endpoints). For studies in which objective response is the primary endpoint, 
diameters greater than 10 mm in two dimensions should be used to define measurable disease.  
Complete response (CR) and unequivocal progressive disease (PD) can likely be 
interpreted even with lesions as small as 5 mm. However, small changes may be difficult to 
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interpret and can be subject to imaging measurement inaccuracies. A minimum change of 25% 
increase in the product of the maximal perpendicular diameters to determine PD or a minimum 
change of 50% decrease in area to determine partial response (PR) from a 5 x 5 mm tumor is 
within the margin of error of measurement and may not be reproducible when two-dimensional 
assessment of MRI data is performed. In addition, because of the intrinsic uncertainty of 
measurements of small lesions, any lesion <10 mm in diameter should be regarded as unchanged 
from baseline unless there is at least a 3 mm change in the measurement. For investigators who 
choose to lower the minimum size limit of measurable disease to 5 mm, we strongly recommend 
MRI imaging with 1.5 mm slice thickness or less. 
The decision to include patients with multiple lesions whose summed area is ≥ 100 mm2 
but whose largest lesion measures less than 100 mm
2
, but greater than 25 mm
2
, should be taken 
with caution when objective response rate is the primary endpoint. If such patients are included, 
response should be assessed using the sum of the products of the maximal diameters of the 
lesions and the response criteria should be clearly delineated in the protocol. Thin section MRI 
with ≤1.5 mm slice thickness would be required in this setting.  
Number of Lesions: 
If there are multiple contrast-enhancing lesions, a minimum of 2, and maximum of 5, of the 
largest lesions should be measured, and the sum of the products of the perpendicular diameters of 
these lesions should be determined, similar to the criteria proposed for gliomas.
14
 In general, the 
largest progressive lesions should be selected. However, emphasis should also be placed on 
lesions that allow reproducible repeated measurements. Occasionally, if the largest lesions do not 
lend themselves to reproducible measurement, the next largest lesions that can be reproducibly 
measured should be selected. For patients with recurrent meningiomas who have multiple 
lesions, of which only one or two are increasing in size, the enlarging lesions should be 
considered the target lesions for evaluation of response. The other lesions will be considered 
non-target lesions and should also be recorded. Rarely, unequivocal progression of a non-target 
lesion requiring discontinuation of therapy or development of a new contrast enhancing lesion 
may occur, even in the setting of stable disease or partial response in the target lesions. Such 
changes should qualify as progression. 
 
Definition of Progression to Allow Clinical Trials Enrollment  
Currently, patients with any worsening of their imaging studies are eligible for entry onto clinical 
trials for recurrent meningioma, even if the change is minimal. Ideally, patients should be 
required to have tumor growth that exceeds a quantifiable and reliable threshold. For high-grade 
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gliomas, it is recommended that patients only become eligible for clinical trials if there is a 25% 
increase in the sum of the products of perpendicular diameters of the contrast-enhancing lesions, 
while on stable or increasing doses of corticosteroids. However, empirically meningioma 
patients are frequently determined to have developed progression based on smaller increases in 
tumor size. For trials where landmark endpoints (e.g. six-month progression-free survival (PFS6) 
are the primary endpoints, it will be important to obtain scans over the same time period before 
therapy (i.e. 6- months for PFS6) to ensure that the prior to enrollment in the clinical trial the 
tumor growth is sufficiently rapid that the tumor will not be considered stable while on study 
simply based on its baseline rate of growth. We therefore recommend that patients are 
considered eligible for clinical trials if there is 15% increase in the sum of the products of 
perpendicular diameters of the contrast enhancing lesions within prior 6 months, while on stable 
or increasing doses of corticosteroids, or if a new lesion develops. Slow-growing meningiomas 
not meeting the criteria should not be included in clinical trials with PFS endpoints; more 
sensitive measures of response such as a change in rate of growth might be more suitable for 
such meningiomas. 
 
Evaluation of Tumor Response and Progression  
General Principles:  
Since meningiomas are almost always enhancing, evaluation of tumor size will be based only on 
the product of the maximal cross-sectional enhancing diameters. There will be no evaluation of 
non-enhancing disease. 
Radiographic response should be determined in comparison to the tumor measurement 
obtained at pretreatment baseline for determination of response, and the smallest tumor 
measurement at either pretreatment baseline or after initiation of therapy should be used for 
determination of progression. Table 1 lists the criteria for radiographic changes after therapy.  
Only patients with measurable disease at baseline should be included in protocols where 
objective tumor response is the primary endpoint. In studies for which objective response is not 
the primary endpoint, the protocol must specify prospectively whether entry is restricted to those 
with measurable disease or if patients with non-measurable disease are also eligible.  
In the event that the radiographic changes are equivocal and it is unclear whether the 
patient is stable or has developed progressive disease, it is permissible to continue treatment and 
observe the patient closely, for example at 8 to 12 -week intervals. If subsequent imaging studies 
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demonstrate that progression has occurred, the date of progression should be the date of the scan 
when criteria for progression were first met.  
 
Minor Response Criteria: 
Given the relatively low rate of response expected, especially for grade I meningioma, we 
propose addition of minor response, characterized by a 25% or greater but less than 50% 
reduction in the product of the maximal perpendicular diameters, similar to the RANO Criteria 
for low-grade gliomas.
15
 
 
Baseline Documentation of Target and Non-Target Lesions:  
All baseline evaluations should be performed as close as possible to the treatment start and not 
more than 4 weeks before the beginning of treatment. A sum of the products of the maximal 
perpendicular diameters for all target lesions will be calculated and reported as the baseline area. 
Target lesions should be measurable. As discussed previously, if there are multiple lesions, at 
least 2, and up to 5, lesions may be selected. All other lesions should be identified as non-target 
lesions and should also be recorded at baseline. Measurements of non-target lesions are not 
required and these should be followed as ‘present’, ‘absent’, or ‘unequivocal progression’.   
 
Definition of Best Overall Response: 
Best overall response represents a composite of target and non-target response (see definitions 
above), as well as corticosteroid use, and clinical status (Table 1). In non-randomized trials 
where response is the primary endpoint, confirmation of PR, MR or CR at a minimum of 8 
weeks, or until the next planned scan per protocol if that is longer, is required to deem either one 
the best overall response.   
At each protocol-specified time point, a response assessment should occur. Table 1 shows the 
additional corticosteroid and clinical status requirements to deem a PR or CR. 
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Evaluation of Target Lesions (Table 1): 
Complete response (CR): Disappearance of all CNS target lesions; sustained for at least 8 
weeks, or until the next planned scan per protocol if that is longer; no new lesions; no or only 
replacement doses of corticosteroids; stable or improved clinically.  
Partial response (PR): At least a >50% decrease compared with baseline in the sum of products 
of perpendicular diameters of all target lesions sustained for at least 8 weeks, or until the next 
planned scan per protocol if that is longer; no new lesions; stable to decreased corticosteroid 
dose compared dose at time of baseline scan; stable or improved clinically.  
Minor response (MR): At least a >25%, but less than 50%, decrease compared with baseline in 
the sum of products of perpendicular diameters of all target lesions sustained for at least 8 weeks, 
or until the next planned scan per protocol if that is longer; no new lesions; stable to decreased 
corticosteroid dose compared dose at time of baseline scan; stable or improved clinically.  
Progressive disease (PD):  Increase by >25% in sum of the products of perpendicular diameters 
of  target lesions compared with the smallest tumor measurement obtained either at baseline (if 
no decrease) or best response; any new lesion; clear progression of non-target; clear clinical 
deterioration not attributable to other causes apart from the tumor (e.g., seizures, medication 
adverse effects, complications of therapy, cerebrovascular events, infection, and so on) or 
changes in corticosteroid dose; or failure to return for evaluation as a result of death or 
deteriorating condition. 
Stable disease (SD): Does not qualify for complete response, partial response, minor response, 
or progression. As with CR, PR and MR, stable disease should be sustained for at least 8 weeks, 
or until the next planned scan per protocol if that is longer. If the corticosteroid dose was 
increased for new symptoms and signs without confirmation of disease progression on 
neuroimaging, and subsequent follow-up imaging shows that this increase in corticosteroids was 
required because of disease progression, the last scan considered to show stable disease will be 
the scan obtained when the corticosteroid dose was equivalent to the baseline dose. 
 
Evaluation of Non-Target Lesions: 
Non-target lesions should be assessed qualitatively at each of the time points specified in the 
protocol and should be sustained for at least 8 weeks similar to the criteria for target lesion 
evaluation. 
CR: Disappearance of all enhancing CNS non-target lesions and no new lesions. 
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Non-CR/Non-PD: Persistence of one or more non-target lesion(s).  
PD: Any of the following: unequivocal progression of existing enhancing non-target lesions, 
new lesion(s) (except while on immunotherapy-based treatment). In the case of immunotherapy-
based treatment, new lesions alone may not constitute progressive disease (see “Guidance in the 
case of new lesion(s) while on immunotherapy” below). 
 
Specific Considerations 
Assessment of target and non-target CNS lesions 
a. Target lesions that become too small to measure: While on study, all CNS target 
lesions should have their actual measurement recorded, even when very small (e.g. 4 x 4 
mm).  If the lesion disappears, the value should be recorded as 0 mm. However, if the 
lesion is sufficiently small (but still present) that the investigator does not feel 
comfortable assigning an exact measure, a minimum of 1 mm can be used for either one 
of the bi-dimensional measurement.  
b. Lesions that coalesce on treatment: As lesions coalesce due to tumor growth, a plane 
between them may be maintained that would aid in obtaining maximum area of each 
individual lesion. If the lesions have truly coalesced such that they are no longer 
separable, the maximal perpendicular diameters of the ‘coalesced’ lesion should be 
measured and compared to the sum of the areas of the preexisting lesions.     
c. Definition of new lesion(s): The finding of a new lesion should be unequivocal and not 
due to technique or slice variation. A new lesion is one that was not present on prior 
scans. If the MRI is obtained with ≤ 1.5 mm slice thickness, then the new lesion should 
also be visible in axial, coronal, and sagittal reconstructions of ≤ 1.5 mm projections. If a 
new lesion is equivocal, for example because of its small size (i.e., < 5 x 5 mm), 
continued therapy may be considered, and follow up evaluation will clarify if it truly 
represents new disease. If repeat scans confirm there is definitely a new lesion, then 
progression should be declared using the date of the initial scan showing the new lesion. 
In the case of immunotherapy, new lesions alone may not constitute progressive disease 
(see “Guidance in the case of new lesion(s) while on immunotherapy” below). 
d. Guidance for special shape or location related challenges in tumor measurement: 
For meningiomas with dural tails that can be distinguished from the main tumor bulk by 
signal intensity, measurements should be applied to the main tumor bulk and not to the 
dural tail. If dural tails cannot readily be discerned from the main tumor as often in the 
case of en plaque meningiomas, the lesion is best regarded as non-measurable by 2D 
criteria but still can be measured by volumetric criteria as outlined below. Similarly, for 
tumors that have ill-defined brain or bone invasion or are distorted in shape by bony 
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hyperostosis making 2D measurement unreliable, the lesion should be regarded as non-
measurable.  For skull base tumors, lesions can be considered measurable only when the tumor 
margins can be well-visualized from extra-osseous structures such as fat or enhancing muscle. In 
these situations, fat suppression technique is necessary to improve visibility of tumor margin.  
We also recognize the difficulty in making consistent 2D measurements in certain anatomical 
locations where the selection of image slice and tumor axis for measurement can be variable.  
To minimize inconsistency, we advise the measurements be made on equivalent image slice and 
tumor axis within the same patient, preferably by the same reader. 
e. Definition of unequivocal progression of non-target lesion(s):  
1. When the patient also has measurable disease, to achieve ‘unequivocal 
progression’ on the basis of non-target disease alone, there must be an overall 
level of substantial worsening in non-target disease such that, even in the presence 
of SD or PR in target disease, the overall tumor burden of all non-target disease 
has increased sufficiently to merit discontinuation of therapy. 
2. When the patient has only non-measurable disease, there must be an overall 
level of substantial worsening so that the tumor is now measurable to merit 
discontinuation of therapy. 
f. Guidance in the case of uncertain attribution of radiographic findings and/or 
equivocal cases: In the case of patients treated by IMRT, SRS, brachytherapy, 
immunotherapies or other targeted approaches that may cause a local inflammatory 
response, there may be radiographic evidence of enlargement of target and non-target 
lesions which may not necessarily represent tumor progression. Although the incidence 
of the phenomenon is not well-known and requires further study, transient tumor growth 
following radiosurgery occurred in 7 patients (8.1%) in a study of 865 meningioma 
patients treated with radiosurgery.
19
 Transient increases in the volume of enhancement 
has also been observed in 3 in 13 (23%) of patients with recurrent WHO grade III 
meningioma treated with boron neutron capture therapy.
20
 Furthermore, in cases of 
invasive meningiomas where enhancing tumor often involves brain parenchyma, it is our 
experience that SRS-induced inflammation/necrosis can be difficult to distinguish from 
true invasive tumor. If there is evidence of radiographic progression in these treatment 
settings, additional evidence is required to distinguish true progression versus treatment 
effect as standard MRI alone is not sufficient. The methods used to distinguish between 
the two entities should be specified prospectively in the clinical protocol. Patients may be 
continued on protocol therapy pending further investigation with one or more of the 
following options: (1) Repeat the scan at the next protocol scheduled evaluation or 
sooner. If there is continued increase in enhancement concerning for tumor growth, then 
this may be consistent with radiographic progression and the patient should be taken off 
study, especially if there is also clinical progression. If the lesion is stable or decreased in 
size, then this may be consistent with treatment effect and the patient may remain on 
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study. For patients with equivocal results even on the next restaging scan, the scan may 
be repeated at a subsequent protocol scheduled evaluation or sooner although surgery 
and/or use of an advanced imaging modality (in the case of SRS) should be considered. 
(2) Surgical pathology obtained via biopsy or resection. (3) For SRS treated lesions, an 
advanced imaging modality such as perfusion MR imaging, MR spectroscopy, or 
positron emission tomography (PET) may be considered to provide additional evidence 
of tumor progression or treatment response.
21
 Regardless of the additional testing 
obtained, if subsequent testing demonstrates that progression has occurred, the date of 
progression should be recorded as the date of the scan at which this issue was first raised. 
Patients may also have an equivocal finding on a scan (for example, a small lesion that is 
not clearly new). It is permissible to continue treatment until the next protocol scheduled 
evaluation. If the subsequent evaluation demonstrates that progression has indeed 
occurred, the date of progression should be recorded as the date of the initial scan where 
progression was suspected.  
g. Guidance in the case of new lesion(s) while on immunotherapy: For patients receiving 
immunotherapies, an initial increase in the size of meningiomas may potentially be 
followed by radiographic stabilization or regression, a similar phenomenon that has been 
seen with other tumors.
22
 This may be related to the mechanism of action for 
immunotherapy, including immune infiltrates, as well as the time required for 
development of an effective immune response. The RANO group has developed an 
Immunotherapy Responses Assessment in Neuro-Oncology (iRANO) Criteria to address 
this issue.
23
 Patients who have received immunotherapies within the past 6 months and 
develop worsening of radiologic findings that would otherwise qualify for PD, may stay 
on study if they are clinically stable. They should be closely followed clinically and with 
neuroimaging studies. If the subsequent evaluation confirms that progression has indeed 
occurred, the date of progression should be recorded as the date of the initial scan where 
progression was suspected. Since inflammatory changes may not resolve over 1 month, 
close observation over period of 3 months may be allowed. As “pseudoprogression” from 
immunotherapies is unlikely to occur later than 6 months after treatment, any radiologic 
progression after this time will be considered true progression. 
a. Corticosteroid Use: Corticosteroids may be indicated in patients with meningioma based 
upon factors such as edema, which can occur in the absence of lesional progression. Thus 
an increase in corticosteroid dose alone, in the absence of clinical deterioration related 
directly to tumor progression, will not be used as a sole determinant of progression. 
Patients with stable imaging studies whose corticosteroid dose was increased for reasons 
other than clinical deterioration related to tumor do not qualify for stable disease or 
progression and should be classified as non-evaluable at that time point. If their 
corticosteroid dose can be reduced back to baseline, they will be considered as having 
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stable disease; if further clinical deterioration related to tumor becomes apparent, they 
will be considered to have progression.   
h. Clinical Deterioration: While the definition of clinical deterioration is left to the 
discretion of the treating physician, it is recommended that a decline in the KPS of at 
least 20 points from baseline, or a decline in KPS from any baseline to 50 or less, for at 
least 7 days, be considered neurologic deterioration unless attributable to comorbid 
events, treatment-related toxicity, or changes in corticosteroid dose. The RANO working 
group has recently proposed Neurologic Assessment in Neuro-Oncology (NANO) 
Criteria to quantify clinical changes more objectively.
24
 The criteria require validation but 
potentially provides a more comprehensive evaluation of neurologic function than KPS.  
i. Volumetric Criteria:  The value of volumetric measurements has been compared to bi-
dimensional measurements in the evaluation of response in brain tumors.
25-28
 For some 
tumors, such as en plaque meningiomas, standard 2-dimensional measurements are very 
difficult and volumetric measurements would be preferable. At present, however, 
performing volumetric analyses in real-time adds cost and complexity and is not available 
at all centers.  At the same time, the RANO Meningioma group believes that evaluation 
and reporting of volumetric response in clinical trials (in addition to the bi-dimensional 
RANO-Meningioma criteria) will add to the knowledge base and either ultimately justify 
or negate the value for volumetric measurements in future trials, and encourages its 
inclusion as a secondary endpoint when feasible. 
The appropriate cut-off that should be chosen to define a partial response when 
volumetric measurements are used is also a matter of debate. Assuming a perfect sphere, 
a bi-dimensional 25% reduction in area corresponds to approximately a 65% volumetric 
reduction, while a bi-dimensional 25% increase in area corresponds to approximately a 
40% volumetric increase. There is evidence showing concordance of response 
assessments when using these cut-offs in other types of brain tumor patients.
27
 At the 
same time, volumetric changes of at least 20% appear to be reproducible between 
readers
29,30
, and in one study were shown to be associated with improvements in 
neurological signs and symptoms.
31
  To provide preliminary support for the use of 
volumetric evaluation in clinical trials, the RANO Meningioma group initiated a multi-
center retrospective study evaluating the MRI imaging data of patients with recurrent 
meningioma enrolled in systemic therapy trials ( article in press). The analysis revealed 
that a 40% increase in tumor volume during the first 6 and 12 months after treatment 
initiation accounts for approximately half of the study population and was associated with 
decreased OS. The use of a 20% volume threshold to define progression did not improve 
correlation with survival, although it remains unclear whether the lower thresholds may 
be associated with other measures of patient benefit such as quality of life, neuro-
cognitive function, or OS.  Criteria using 65%, 40% and 20% thresholds of volume 
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reduction identified a small percentage of responders, and no survival advantage was 
demonstrated among the responders regardless of criteria used.  
The group believes that the use of the same criteria and cut-offs across trials will 
allow trial results to be placed into their proper context.  It is also important to recognize 
that the correlative relationship between 2D and volume measurements may alter due to 
differences in 3D shape and comparing trial results using different endpoints (2D vs 
volume) is currently not advised.  Thus, for investigators who choose to report volumetric 
response data, we propose the following (Table 2): 
1. Progressive disease will be defined as > 40% increase in the sum of tumor volume of 
CNS target lesions in addition to the corticosteroid and clinical status criteria as 
outlined previously. 
2. Partial volumetric response will be defined as > 65% decrease in the sum volume of 
CNS target lesions, in addition to the corticosteroid and clinical status criteria as 
outlined previously. 
3. It may be possible to consider a lower threshold for volumetric response and we 
encourage digital archiving of trial images and accompanying linked clinical outcome data to 
allow for pooling of studies to determine whether different thresholds might be justified in 
the future. 
 
Imaging Protocol Recommendations 
To improve the reproducibility of imaging response assessment and to facilitate 
comparisons across clinical trials, a standardized imaging protocol is necessary. The 
brain tumor imaging protocol (BTIP) published recently includes a gadolinium enhanced 
3-dimensional (3D) T1-weighted imaging with less than 1.5 mm slice thickness
17
.  This 
protocol specifies parameters that can be readily implemented on modern scanners and 
should allow both diameter and volumetric measurement for most intracranial 
meningiomas. Additional sequences including T2-weighted imaging and diffusion 
weighted imaging specified in the BTIP protocol may facilitate evaluation of advanced 
imaging analysis and identification of novel imaging biomarkers for future refinement of 
response assessment criteria. For meningiomas that involve the cranium, skull base, or 
extracranial spaces, we recommend applying fat-suppression techniques such as water 
excitation to the 3D T1-weightd sequence for better delineation of tumor margins from 
bone marrow.  This also allows distinction of tumor from fat graft material commonly 
used during surgical resection of skull base meningiomas.  We recognize that the option 
to apply fat suppression on some MR platforms is not available, and therefore alterations 
to the technique as specified in the BTIP protocol may be necessary.  In principle, the 3D 
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T1-weighted sequence should have an isotropic resolution of less than 1.5 mm and should 
have the option to include water excitation fat-suppression technique that has less artifact 
related to field inhomogeneity. It is also necessary to include the full extent of tumor in 
the 3D sequence.  
 
Summary 
We propose response criteria for evaluation of therapies for meningioma in order to achieve 
consistency across clinical trials. These recommendations were generated as part of an 
international neuro-oncology effort toward consensus building. Implementation into future 
clinical trials will be critical to allow these criteria to be evaluated and validated. These criteria 
are a work in progress and we expect them to be iteratively updated as data and experience 
accrue. 
 
Endpoints In Meningioma Clinical Trials 
The determination of best clinical trial endpoints for meningioma has many of the same 
challenges encountered in other cancers trying to define a true OS advantage with therapy but 
having to rely on surrogate endpoints.  Meningioma is complicated by the large spectrum of 
clinical symptoms that can occur depending on its size and location, and employing therapies at 
different time points can have very different results.  Demonstrating an OS benefit represents the 
unequivocal gold standard of treatment efficacy. However, OS is also the most difficult to 
ascertain owing to the long time frame often needed to reach this endpoint, and the large amount 
of resources needed to perform such studies.   
Therefore, similar to other cancers, meningioma trials have relied on surrogate endpoints 
to determine treatment efficacy. However, this must be done with caution as these surrogates, 
such as PFS, 6-month PFS rate (PFS6), and radiographic objective response rate (ORR), have 
not been shown to correlate with an OS advantage.  With regards to brain tumors, even a PFS 
advantage may be meaningful in the absence of a true OS benefit owing to a potential reduction 
in neurologic morbidity.  Here, we describe various clinical trial endpoints, and where in the 
disease course they may be most appropriate.  
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Objective Response Rate (ORR) 
Objective response rate (ORR) is usually viewed as a strong indicator of a treatment’s 
activity. However, ORR following therapies for meningiomas have generally been very low. It is 
likely that this results from the use of ineffective therapies as well as factors related to inherent 
tumor biology.  In a RANO review of the results of medical therapies for meningioma, 37 of 42 
publications reported radiographic response data.  Of the 555 patients included in those 37 
reports, best radiographic responses were reported as 1 CR (0.2%), 10 PR (1.8%), 13 MR 
(2.3%), and 343 SD (62%).  Therefore, the combined CR + PR + MR rate was 4.3% suggesting 
that reduction in tumor size has been only rarely observed.  However, once SD is included, the 
“potential clinical benefit rate” is much higher.   
The inclusion of SD raises an interesting predicament. Meningiomas refractory to surgery 
and radiation therapy often grow quickly and have a weighted average PFS6 rate of 29% for the 
WHO grade I group and 26% for the WHO grade II and III group.
9
 In such aggressive tumors, 
SD may be considered indicative of an active treatment.  However, the poor PFS results despite 
the relatively high SD rates reported suggests that these SD responses were either in patients that 
were not progressing quickly enough to qualify for progressive disease on the first imaging 
timepoint, or the drug’s effects were not durable.  In either situation, simply attaining short 
duration SD as a best radiographic response is not a reliable surrogate endpoint for a drug’s 
efficacy.  However, since CR/PR/MR responses are infrequent, it is perhaps more clinically 
relevant to include SD as a response but impose some time limit modifications to qualify as a 
response.  For example, lack of PD, CR, PR, MR on imaging over an interval of less than 6 
months should not be considered clinically relevant SD. 
 
Progression-Free Survival  
    PFS is defined as the time from the initiation of the treatment under study until the time 
of documented disease progression or death, whichever occurs first. The advantage of PFS is that 
it represents the effect of the treatment under study, thus eliminating the effect of post-
progression therapies which can complicate the interpretation of OS as an endpoint.  
In the RANO review of published clinical trials of medical therapies in meningiomas 
PFS6 was the only outcome reported with sufficient frequency to provide historical comparisons 
for clinical trials.
9
 Additionally, given the concern over the high SD rates yet the poor PFS6 
rates, it is likely that the 6 month time point eliminates most patients who are called SD but 
really are just progressing too slowly to reach the 25% growth threshold required for PD 
determination in most of these studies.  
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For trials where PFS or landmark endpoints (e.g. PFS6) are the primary endpoints, it will 
be important to obtain scans over the previous 6-12 months to ensure that the rate of growth prior 
to enrollment in the clinical trial is sufficiently rapid that the tumor will not be considered stable 
while on study simply based on its slow baseline rate of growth. 
From the historic data indicating that PFS6 for negative trials of WHO grade I 
meningioma is 29%, an increase of the PFS6 to 50% would probably be of interest. For WHO 
grade II and III meningioma where the historic PFS6 is 26%, an increase of PFS6 to 40% would 
probably be of interest in single arm studies.
9
  
Ideally, trials using a PFS endpoint would be randomized since it can be difficult to 
ensure that the patients enrolled in the trial matches the historic controls. However, given the 
small number of meningioma patients available for accrual into clinical trials and paucity of 
testable/established therapies, most meningioma studies will likely include only a single arm. In 
these studies, it will be important to ensure as much as possible that the patients match the 
historic controls that they are being compared to, particularly with regard to relevant 
demographic factors, histopathologic grade, degree of prior treatment and extent of surgery. 
 Irradiation (especially SRS) and immunotherapies may result in “pseudoprogression” 
complicating the interpretation of PFS as an endpoint, although this issue is probably less 
common than with gliomas.  
Given the limitations of both ORR and PFS as endpoints, some trials, such as the 
Alliance trial evaluating targeted agents for recurrent meningioma (NCT02523014) uses a co-
primary endpoint of ORR and PFS6, in which therapeutic success of the trial will be defined by 
either endpoint criterium being satisfied.  
 
Overall Survival 
OS remains the unequivocal measure of a treatment’s effectiveness.  However, in trying 
to evaluate the effectiveness of newer therapies, OS is hindered by a real lack of historical 
comparative data as the reporting of OS data was quite minimal in the previous RANO 
reviews.
7,9
  Without reliable historical comparison, OS is only useful in randomized studies.  
Moreover, the very long timelines, the influence of post-progression therapies, and the extensive 
resources required for large randomized studies make this endpoint unrealistic for most 
meningioma trials. 
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Other Endpoints 
Given the limitations of the currently available standard endpoints there is interest in novel 
endpoints for meningioma trials. Since radiographic response is uncommon, one endpoint under 
evaluation is whether therapies under consideration can decrease the rate of tumor volume 
growth. A local control endpoint, which is inclusive of stability or response, has been commonly 
employed for trials following radiosurgery, external beam radiation therapy, and surgery with 
subtotal resection. Data from completed meningioma clinical trials are currently being analyzed 
and the utility of this approach will be reported separately. Other non-radiological endpoints, not 
limited but including quality of life, seizure frequency, time to second line treatment or cognitive 
function will not be discussed in this paper.  
 
Meningioma Clinical Trial Endpoints Recommendations 
In summary, as radiographic responses are rare in meningioma inclusion of SD seems clinically 
appropriate as cessation of growth of these tumors should be considered beneficial given the 
poor survival of these patients and the neurologic morbidity from tumor growth. Therefore, an 
appropriate endpoint for medical therapy trials in surgery and radiation refractory meningioma is 
either PFS6 rate or a combination of PFS6 and radiographic response.  
 
Summary 
To address the variability in response criteria and endpoints used in meningioma clinical trials, 
the RANO group has proposed updated criteria for assessing response and selecting endpoints in 
these trials. These criteria are in work in progress. These recommendations will need validation 
in future clinical trials and eventually may require updating. 
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Table 1. Summary of the Proposed RANO Response Criteria for Meningiomas 
Criterion CR PR MR SD PD 
Target lesions None ≥ 50% decrease 
in area relative 
to baseline 
≥ 25% and < 
50% decrease 
in area relative 
to baseline  
< 25% decrease 
relative to 
baseline but < 
25% increase in 
area relative to 
nadir 
≥ 25% increase 
in area relative 
to nadir* 
Non-target 
lesions 
None Stable or 
improved 
Stable or 
improved 
Stable or 
improved 
Unequivocal 
PD* 
New lesion(s)** None None None None Present* 
Corticosteroids None Stable or 
decreased 
Stable or 
decreased 
Stable or 
decreased 
NA
+
 
Clinical status Stable or 
improved 
Stable or 
improved 
Stable or 
improved 
Stable or 
improved 
Worse* 
Requirement for 
response 
All All All All Any
+
 
 
Abbreviations: CNS, central nervous system; RANO, Response Assessment in Neuro-Oncology; CR, 
complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not applicable  
*Progression occurs when this criterion is met.  
**New lesion = new lesion not present on prior scans and visible in at least 2 projections.  If a new lesion 
is equivocal, for example because of its small size, continued therapy may be considered, and follow up 
evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new 
lesion, then progression should be declared using the date of the initial scan showing the new lesion. For 
immunotherapy-based approaches, new lesions alone to do not define progression (See “Guidance in the 
case of new lesion(s) while on immunotherapy”). 
+
Increase in corticosteroids alone will not be taken into account in determining progression in the absence 
of persistent clinical deterioration. 
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Table 2. Summary of the Proposed RANO Volumetric Response Criteria for Meningiomas 
Criterion CR PR MR SD PD 
Target lesions None ≥ 65% decrease 
in volume 
relative to 
baseline 
≥ 40% and < 
65% decrease 
in volume 
relative to 
baseline  
< 40% decrease 
relative to 
baseline but < 
40% increase in 
volume relative 
to nadir 
≥ 40% increase 
in volume 
relative to nadir* 
Non-target 
lesions 
None Stable or 
improved 
Stable or 
improved 
Stable or 
improved 
Unequivocal 
PD* 
New lesion(s)** None None None None Present* 
Corticosteroids None Stable or 
decreased 
Stable or 
decreased 
Stable or 
decreased 
NA
+
 
Clinical status Stable or 
improved 
Stable or 
improved 
Stable or 
improved 
Stable or 
improved 
Worse* 
Requirement for 
response 
All All All All Any
+
 
 
Abbreviations: CNS, central nervous system; RANO, Response Assessment in Neuro-Oncology; CR, 
complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not applicable  
*Progression occurs when this criterion is met.  
**New lesion = new lesion not present on prior scans and visible in at least 2 projections.  If a new lesion 
is equivocal, for example because of its small size, continued therapy may be considered, and follow up 
evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new 
lesion, then progression should be declared using the date of the initial scan showing the new lesion. For 
immunotherapy-based approaches, new lesions alone to do not define progression (See “Guidance in the 
case of new lesion(s) while on immunotherapy”). 
+
Increase in corticosteroids alone will not be taken into account in determining progression in the absence 
of persistent clinical deterioration. 
 
 
Downloaded from https://academic.oup.com/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/noy137/5076187
by guest
on 18 August 2018
